Celcuity Inc. (NASDAQ:CELC) Shares Sold by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. reduced its stake in Celcuity Inc. (NASDAQ:CELC - Free Report) by 91.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,484 shares of the company's stock after selling 301,469 shares during the quarter. Balyasny Asset Management L.P. owned about 0.07% of Celcuity worth $347,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the stock. Bleakley Financial Group LLC acquired a new stake in shares of Celcuity in the fourth quarter worth $146,000. Corebridge Financial Inc. boosted its stake in shares of Celcuity by 12.9% in the fourth quarter. Corebridge Financial Inc. now owns 16,256 shares of the company's stock worth $213,000 after buying an additional 1,858 shares during the last quarter. Vanguard Group Inc. grew its holdings in Celcuity by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock worth $21,624,000 after acquiring an additional 24,429 shares during the period. Charles Schwab Investment Management Inc. raised its position in Celcuity by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company's stock valued at $3,112,000 after acquiring an additional 16,035 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Celcuity by 21.6% in the 4th quarter. Wellington Management Group LLP now owns 62,776 shares of the company's stock worth $822,000 after purchasing an additional 11,165 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CELC shares. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Monday. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Celcuity in a report on Thursday, May 15th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Celcuity currently has an average rating of "Buy" and a consensus target price of $30.80.

Celcuity Price Performance

CELC stock traded down $0.18 during mid-day trading on Wednesday, reaching $10.48. The company's stock had a trading volume of 59,628 shares, compared to its average volume of 297,472. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company's 50 day moving average is $10.16 and its two-hundred day moving average is $11.60. Celcuity Inc. has a fifty-two week low of $7.58 and a fifty-two week high of $19.77. The stock has a market cap of $396.36 million, a PE ratio of -4.01 and a beta of 0.56.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. Equities research analysts expect that Celcuity Inc. will post -2.62 EPS for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.